UNASSIGNED: In order to study @entity4990 ( @entity4991 ) signaling associated with type  1 @entity1204 ( @entity1204 ), we evaluated the @entity4991 receptors (LPARs), @entity23927 ( @entity23927 ) and @entity3900 ( @entity3900 ) expression in @entity1204 and normal endometrium with correlation to clinicopathological features. We investigated @entity25068 , @entity42659 , @entity45232 , @entity68176 , @entity23927 and @entity3900 expression at mRNA and protein levels using quantitative real-time PCR and western blot analyses in 37  ECs and 10  normal endometria. All the examined LPARs (except for @entity45232 protein), @entity23927 and @entity3900 were overexpressed in cancerous compared to healthy endometrium. The studied ECs showed the highest @entity42659 and @entity25068 expression. Statistically positive correlations were found between depth of myoinvasion and levels of @entity25068 , @entity42659 and @entity3900 transcripts and proteins. We also found positive correlations between @entity25068 , @entity42659 , @entity68176 and @entity3900 expression with the International Federation of Gynecology and Obstetrics (FIGO) stage. The expression of @entity25068 , @entity42659 and @entity3900 was positively associated with the age of @entity1 . Positive correlations were found between the expression of @entity25068 mRNA, @entity42659 mRNA and protein and @entity45232 mRNA and body mass index (BMI) of the examined @entity1 . We found no association between the expression levels of the studied factors and @entity6 or @entity101 among the examined @entity1 . Owing to the highest @entity42659 and @entity25068 expression in @entity1204 and positive correlations of these two receptors with the depth of myoinvasion and the FIGO stage, we believe that @entity42659 and @entity25068 show promise as predictors of the @entity1204 progression as well as the main receptors responsible for @entity4991 action in the @entity1204 tissue.

The significance of the altered expression of XXXX receptors, @entity23927 and @entity3900 as the potential biomarkers in type  1 @entity1204 biology.

@entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial carcinoma', 'EC'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity4990 :: ('MESH:C032881', 'Chemical') :: ['lysophosphatidic acid'] @entity68176 :: ('2846', 'Gene') :: ['LPAR4'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity4991 :: ('CHEBI:52288', 'Chemical') :: ['LPA'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity3900 :: ('151056', 'Gene') :: ['phospholipase  A2', 'PLA2'] @entity45232 :: ('23566', 'Gene') :: ['LPAR3'] @entity23927 :: ('5168', 'Gene') :: ['ATX', 'autotaxin'] @entity42659 :: ('9170', 'Gene') :: ['LPAR2'] @entity25068 :: ('1902', 'Gene') :: ['LPAR1']
@entity4990 :: (MESH:C032881,Chemical) :: ['lysophosphatidic acid']
